Last reviewed · How we verify
De-prescribe beta blocker therapy — Competitive Intelligence Brief
marketed
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
De-prescribe beta blocker therapy (De-prescribe beta blocker therapy) — University of Saskatchewan. This is a clinical deprescribing protocol that guides the gradual discontinuation of beta-blocker medications in patients for whom continued therapy is no longer indicated.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| De-prescribe beta blocker therapy TARGET | De-prescribe beta blocker therapy | University of Saskatchewan | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- De-prescribe beta blocker therapy CI watch — RSS
- De-prescribe beta blocker therapy CI watch — Atom
- De-prescribe beta blocker therapy CI watch — JSON
- De-prescribe beta blocker therapy alone — RSS
Cite this brief
Drug Landscape (2026). De-prescribe beta blocker therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/de-prescribe-beta-blocker-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab